Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 Effects on Hypoglycemia Responses in T1DM
NCT04355832Phase 1Withdrawn
- Sponsor
- University of Maryland, Baltimore
- Start
- Jun 2020
- Primary completion
- Sep 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Glucagon-like peptide 1 in type 1 diabetes mellitus (T1D) (3 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Change in the level of catecholamines in plasma at 3 years. Planned start Jun 2020; status: withdrawn.
02
Drugs
Glucagon-like peptide 1
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04355832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04355832.